DK1282438T3 - Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII - Google Patents

Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII

Info

Publication number
DK1282438T3
DK1282438T3 DK01931458T DK01931458T DK1282438T3 DK 1282438 T3 DK1282438 T3 DK 1282438T3 DK 01931458 T DK01931458 T DK 01931458T DK 01931458 T DK01931458 T DK 01931458T DK 1282438 T3 DK1282438 T3 DK 1282438T3
Authority
DK
Denmark
Prior art keywords
factor
pharmaceutical composition
xiii
viia
factor viia
Prior art date
Application number
DK01931458T
Other languages
English (en)
Inventor
Lars Christian Petersen
Ulla Hedner
Rasmus Rojkjaer
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of DK1282438T3 publication Critical patent/DK1282438T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK01931458T 2000-05-10 2001-05-10 Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII DK1282438T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
US20619400P 2000-05-22 2000-05-22
US20621200P 2000-05-22 2000-05-22
DKPA200000871 2000-06-06
US21285700P 2000-06-20 2000-06-20

Publications (1)

Publication Number Publication Date
DK1282438T3 true DK1282438T3 (da) 2005-11-14

Family

ID=27222387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01931458T DK1282438T3 (da) 2000-05-10 2001-05-10 Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII

Country Status (17)

Country Link
US (3) US20030092627A1 (da)
EP (3) EP1282438B1 (da)
JP (2) JP2004505016A (da)
CN (1) CN1304049C (da)
AT (2) ATE311198T1 (da)
AU (3) AU2001258228B2 (da)
BR (1) BR0110659A (da)
CA (1) CA2406583A1 (da)
CZ (1) CZ20023667A3 (da)
DE (2) DE60112429T2 (da)
DK (1) DK1282438T3 (da)
ES (2) ES2254414T3 (da)
HU (1) HUP0301868A3 (da)
IL (1) IL152554A0 (da)
NO (1) NO20025355L (da)
PL (1) PL365042A1 (da)
WO (2) WO2001085199A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211886B1 (pl) * 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CA2420892A1 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
EP1337267B1 (en) * 2000-11-03 2007-04-25 ZymoGenetics, Inc. Use of blood coagulation factor xiii for treating haemophilia a
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
ES2288524T3 (es) * 2000-11-10 2008-01-16 Zymogenetics, Inc. Factor xiii en combinacion con factor ix para tratar la hemofilia b.
PL365290A1 (en) * 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
EP1379271A1 (en) * 2001-02-21 2004-01-14 ZymoGenetics, Inc. Method for treating von willebrand's disease
WO2003022305A1 (en) * 2001-09-10 2003-03-20 Zymogenetics, Inc. Method for treating coumarin-induced hemorrhage
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
WO2003039581A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003039582A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
HUP0402315A3 (en) * 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
KR101006070B1 (ko) * 2001-12-21 2011-01-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 액체 조성물
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
PT1599222E (pt) * 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Composições aquosas estabilizadas que contêm um inibidor da via do factor tecidular (tfpi) ou uma variante do inibidor da via do factor tecidular
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
EP1750758A1 (en) * 2004-05-11 2007-02-14 Novo Nordisk Health Care AG Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
WO2006021584A2 (en) * 2004-08-27 2006-03-02 Novo Nordisk Health Care Ag Purification of factor xiii polypeptides from biological materials
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
ATE540974T1 (de) 2004-11-23 2012-01-15 Zymogenetics Inc Reinigung des rekombinanten menschlichen faktors xiii
WO2006089966A2 (en) * 2005-02-28 2006-08-31 Novo Nordisk Health Care Ag Fxiii variants with improved properties
EP1919499A2 (en) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
DK2004214T3 (da) 2006-03-16 2013-02-18 Stellaris Pharmaceuticals Aps Lokalbehandling med faktor VII
EP2046372A2 (en) * 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Factor viia analogues with increased activity for treating thrombocytopenia
EP2147096B1 (en) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CA2722230C (en) 2008-04-21 2016-08-23 Novo Nordisk Health Care Ag Dry transglutaminase composition
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
ES2773766T3 (es) * 2008-12-19 2020-07-14 Baxalta GmbH Inhibidores de TFPI y métodos de uso
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
WO2020021890A1 (ja) 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
ATE66374T1 (de) * 1985-11-26 1991-09-15 Novo Nordisk As Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
WO1993006855A1 (en) * 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
EP0885020A1 (en) * 1996-02-20 1998-12-23 Cohesion Corporation Tissue sealant compositions and methods of use thereof
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
AU2094199A (en) * 1997-12-23 1999-07-12 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
EP1076698A2 (en) * 1998-05-14 2001-02-21 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors
EP1148427A1 (en) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Method of and system for creating a button type bookmark in a web browser displaying a user-selected part of the corresponding data file
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
PL365290A1 (en) * 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2003039582A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物

Also Published As

Publication number Publication date
EP1282439B1 (en) 2005-11-30
WO2001085199A1 (en) 2001-11-15
CN1304049C (zh) 2007-03-14
AU2001258228B2 (en) 2006-01-12
US20070280920A1 (en) 2007-12-06
ES2247106T3 (es) 2006-03-01
JP2004505016A (ja) 2004-02-19
ES2254414T3 (es) 2006-06-16
IL152554A0 (en) 2003-05-29
CN1429117A (zh) 2003-07-09
US20030092627A1 (en) 2003-05-15
NO20025355D0 (no) 2002-11-08
CA2406583A1 (en) 2001-11-15
EP1593389A1 (en) 2005-11-09
HUP0301868A3 (en) 2006-11-28
ATE300953T1 (de) 2005-08-15
AU2001258230A1 (en) 2001-11-20
NO20025355L (no) 2003-01-09
AU5822801A (en) 2001-11-20
CZ20023667A3 (cs) 2003-04-16
EP1282438A1 (en) 2003-02-12
WO2001085198A1 (en) 2001-11-15
BR0110659A (pt) 2003-02-11
EP1282439A1 (en) 2003-02-12
ATE311198T1 (de) 2005-12-15
HUP0301868A2 (hu) 2003-08-28
DE60112429T2 (de) 2006-06-01
DE60115422D1 (de) 2006-01-05
DE60112429D1 (de) 2005-09-08
EP1282438B1 (en) 2005-08-03
DE60115422T2 (de) 2006-08-17
PL365042A1 (en) 2004-12-27
US20060199766A1 (en) 2006-09-07
JP2003532684A (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
DK1282438T3 (da) Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII
SE0102315D0 (sv) Compounds
DE69939370D1 (de) Medizinischer artikel aus unterschiedlich hergestelltem kollagen-biomaterial
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
ATE380054T1 (de) Topisches mittel zur dermatologischen verwendung enthaltend 4-hydroxyphenyl-alpha-d-glucopyranosid
HK1059215A1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
AR027968A1 (es) Una composicion para utilizar en el tratamiento y/o prevencion del sarampion y el uso de dicha composicion para un vehiculo para el tratamiento o prevencion del sarampion
DK1280500T3 (da) Synergistisk oral sammensætning mod plak og gingivitis
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
DE60126266D1 (de) Verfahren zur oligomerisierung von alkenen
EE200300134A (et) Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena
DE60135451D1 (de) Gebrauch von polyphosphat zum verhindern von zahnerosion in sauren zusammensetzungen
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
DE60204584D1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
ITTO20010804A0 (it) Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
DE60225446D1 (de) Flammgeschützte zusammensetzung und artikel
NO20014946L (no) Strukturerte multiformåls-pakkinger og deres anvendelse
IT1318556B1 (it) Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni
DK1423429T3 (da) Antistoffer mod caspase-8 og deres fremstilling og anvendelse
ATE363273T1 (de) Verwendung von itakonsäure zur regulierung des glykolytischen stoffwechsels
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
BR8000753U (pt) Balão de inflar para decoração e folguedos
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome